Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma
Metadata
Show full item recordAuthor
Lavarino, Cinzia; Cheung, Nai-Kong V.; García, Idoia; Domenech, Gema; Torres, Carmen de; Alaminos Mingorance, Miguel; Ríos, José; Gerald, William L.; Kushner, Brian; LaQuaglia, Mike; Mora, JaumeEditorial
Biomed Central
Materia
Chromosome aberrations Gene expression profiling Neoplastic Neoplasm staging Neoplastic processes Neuroblastoma
Date
2009Referencia bibliográfica
Lavarino, C.; et al. Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma. BMC Cancer, 9:44 (2009). [http://hdl.handle.net/10481/30774]
Sponsorship
This work was supported by: Career Development Award 2001 (to J. M.) from the American Society of Clinical Oncology (ASCO). The Developmental tumour biology laboratory, Hospital Sant Joan de Déu in Barcelona, is supported by grants from the Spanish Ministry of Health (Redes Temáticas de Investigación Cooperativa 2002;G03/089), the Catalan government (AGAUR, Generalitat de Catalunya, 2005SGR00605), and the generous gift from Fondo Margarita del Pozo to the laboratory. Supported in part by the National Cancer Institute grant CA106450 (NKC and WG), The Robert Steel Foundation (NKC), Hope Street Kids (NKC), and Katie's Find A Cure Fund (NKC).Abstract
Background: Neuroblastoma (NB) tumours have the highest incidence of spontaneous remission,
especially among the stage 4s NB subgroup affecting infants. Clinical distinction of stage 4s from
lethal stage 4 can be difficult, but critical for therapeutic decisions. The aim of this study was to
investigate chromosomal alterations and differential gene expression amongst infant disseminated
NB subgroups. Methods: Thirty-five NB tumours from patients diagnosed at < 18 months (25 stage 4 and 10 stage
4s), were evaluated by allelic and gene expression analyses. Results: All stage 4s patients underwent spontaneous remission, only 48% stage 4 patients
survived despite combined modality therapy. Stage 4 tumours were 90% near-diploid/tetraploid,
44% MYCN amplified, 77% had 1p LOH (50% 1p36), 23% 11q and/or 14q LOH (27%) and 47% had
17q gain. Stage 4s were 90% near-triploid, none MYCN amplified and LOH was restricted to 11q.
Initial comparison analyses between stage 4s and 4 < 12 months tumours revealed distinct gene
expression profiles. A significant portion of genes mapped to chromosome 1 (P < 0.0001), 90% with
higher expression in stage 4s, and chromosome 11 (P = 0.0054), 91% with higher expression in
stage 4. Less definite expression profiles were observed between stage 4s and 4 < 18m, yet,
association with chromosomes 1 (P < 0.0001) and 11 (P = 0.005) was maintained. Distinct gene
expression profiles but no significant association with specific chromosomal region localization was
observed between stage 4s and stage 4 < 18 months without MYCN amplification. Conclusion: Specific chromosomal aberrations are associated with distinct gene expression
profiles which characterize spontaneously regressing or aggressive infant NB, providing the
biological basis for the distinct clinical behaviour.